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Cotton rat immune responses 
to virus-like particles containing the pre-fusion 
form of respiratory syncytial virus fusion protein
Lori McGinnes Cullen1, Jorge C. G. Blanco3 and Trudy G. Morrison1,2*
Abstract 
Background: Virus-like particles (VLPs) based on Newcastle disease virus (NDV) core proteins, M and NP, and con-
taining two chimera proteins, F/F and H/G, composed of the respiratory syncytial virus (RSV) fusion protein (F) and 
glycoprotein (G) ectodomains fused to the transmembrane and cytoplasmic domains of the NDV F and HN proteins, 
respectively, stimulate durable, protective anti-RSV neutralizing antibodies in mice. Furthermore, immunization of 
mice with a VLP containing a F/F chimera protein with modifications previously reported to stabilize the pre-fusion 
form of the RSV F protein resulted in significantly improved neutralizing antibody titers over VLPs containing the wild 
type F protein. The goal of this study was to determine if VLPs containing the pre-fusion form of the RSV F protein 
stimulated protective immune responses in cotton rats, a more RSV permissive animal model than mice.
Methods: Cotton rats were immunized intramuscularly with VLPs containing stabilized pre-fusion F/F chimera 
protein as well as the H/G chimera protein. The anti-RSV F and RSV G antibody responses were determined by ELISA. 
Neutralizing antibody titers in sera of immunized animals were determined in plaque reduction assays. Protection 
of the animals from RSV challenge was assessed. The safety of the VLP vaccine was determined by monitoring lung 
pathology upon RSV challenge of immunized animals.
Results: The Pre-F/F VLP induced neutralizing titers that were well above minimum levels previously proposed to 
be required for a successful vaccine and titers significantly higher than those stimulated by RSV infection. In addition, 
Pre-F/F VLP immunization stimulated higher IgG titers to the soluble pre-fusion F protein than RSV infection. Cotton 
rats immunized with Pre-F/F VLPs were protected from RSV challenge, and, importantly, the VLP immunization did not 
result in enhanced respiratory disease upon RSV challenge.
Conclusions: VLPs containing the pre-fusion RSV F protein have characteristics required for a safe, effective RSV 
vaccine.
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Background
Respiratory syncytial virus (RSV) is a very serious patho-
gen in several different human populations. The virus is 
the most significant viral cause of lower respiratory tract 
infections in infants and young children. Nair et al. esti-
mated that world wide there are annually 34 million acute 
lower respiratory tract infections due to RSV with 3.8 
million infections requiring hospitalization and 160,000–
199,000 deaths [1]. Elderly populations are also at risk for 
serious RSV disease, accounting for 10,000 deaths and 
14,000–60,000 hospitalizations per year in the US among 
individuals greater than 64 years of age [2–4]. RSV infec-
tion in immunocompromised populations, particularly 
stem cell transplant recipients [5] and individuals with 
cardiopulmonary diseases [6], can be life threatening.
Despite the impact of this virus on human health, no 
licensed vaccine exists. A major problem for RSV vac-
cine development has been a lack of understanding of 
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requirements for generation of protective immunity to 
RSV infection. In contrast to most viral infections, RSV 
infection does not induce durable protective antibod-
ies in humans. Humans can experience repeated infec-
tions caused by the same serotype of RSV many times 
over years or even within the same season [7, 8]. Simi-
larly vaccine candidates thus far tested have failed to 
induce high levels of neutralizing antibodies and protec-
tion from virus challenge in human trials (reviewed in [9, 
10]) although they may be protective in murine models. 
One important issue has been a lack of understanding of 
the most effective form of the RSV antigens, particularly 
the F protein, for stimulating potent human neutralizing 
antibodies.
The paramyxovirus F protein exists in two very differ-
ent conformations, a metastable pre-fusion form and a 
very stable post-fusion form [11, 12]. It is proposed that 
the protein is initially folded into the pre-fusion conforma-
tion. Upon fusion activation at initiation of infection, the 
molecule refolds through a series of conformational inter-
mediates into a stable post-fusion conformation and, in 
the process, mediates membrane fusion between the viral 
membrane and target host cell membranes [11–18]. While 
the pre-fusion form of F protein should be most effective 
in stimulating optimally neutralizing antibodies, recent 
studies have shown that the post-fusion form contains 
at least some epitopes recognized by neutralizing mono-
clonal antibodies [16, 17]. Thus, it has been argued that 
a post-fusion F protein can be used as a vaccine [19] and 
this form of F protein is now in clinical trials. However, 
Magro et  al. reported that most of the neutralizing anti-
bodies in polyclonal human or rabbit anti-RSV immune 
sera do not bind to the post-fusion F protein [20] leading 
them to suggest that the majority of effective human neu-
tralizing antibody binding sites reside on the pre-fusion F 
protein and not the post-fusion form. Supporting this idea, 
McLellan and colleagues have defined an antigenic site ф 
not present on the post-fusion form of the protein [18] and 
showed that monoclonal antibodies specific for this site 
neutralized RSV at significantly lower concentrations than 
antibodies specific for sites present on both the pre- and 
post-fusion forms of the protein. Furthermore, McLellan 
et  al. [21] identified mutations in the F protein ectodo-
main that stabilized the pre-fusion form of the protein and 
reported that soluble forms of stabilized pre-fusion of pro-
tein, in the presence of adjuvant, stimulated significantly 
higher neutralizing antibody titers, in both mice and non 
human primates, than those elicited by post-fusion forms.
We have recently explored the use of virus-like parti-
cles (VLPs) as vaccine candidates for RSV [22, 23]. Virus-
like particles (VLPs) are now recognized as safe, effective 
vaccines for several viral diseases [24], notably those due 
to hepatitis B virus and human papilloma virus infections 
[24]. VLPs are virus-sized particles composed of repeating 
native structural arrays on their surfaces and in their cores, 
structures that mimic those of infectious viruses and con-
tribute to their very potent immunogenicity [24–26]. We 
have recently developed novel VLPs containing RSV glyco-
proteins that induce, in mice, protective anti-RSV immune 
responses [22, 23]. These VLPs are based on the structural 
core proteins, nucleocapsid protein (NP) and matrix (M) 
protein, of Newcastle disease virus (NDV). To accomplish 
assembly of the RSV glycoproteins into these VLPs (ND 
VLPs), the ectodomains of the RSV F and G proteins were 
fused to the transmembrane (TM) and cytoplasmic tail 
(CT) sequences of the NDV fusion (F) and hemagglutinin-
neuraminidase (HN) proteins, respectively, creating RSV 
F/NDV F (F/F) and NDV HN/RSV G (H/G) chimera pro-
teins. VLPs containing these chimera proteins are highly 
immunogenic and stimulated both anti-RSV F protein and 
anti-RSV G protein specific antibodies in the absence of 
adjuvant [22, 23]. Recently, we reported the assembly, into 
these VLPs, of the ectodomain of the RSV F protein con-
taining the mutations reported by McLellan et  al. to sta-
bilize the pre-fusion [21] or the post-fusion forms of this 
protein [17] and showed that, in mice and without adju-
vant, the VLP associated pre-fusion F protein stimulated 
significantly higher titers of neutralizing antibodies than 
the VLP associated post-fusion F protein or wild type pro-
tein after a single immunization [27].
Cotton rats, which are more permissive to RSV infec-
tions than mice, are an accepted standard animal model 
for RSV [28]. Positive results in this model with vac-
cine candidates, anti-viral drugs, or antibodies have led 
directly to human trials. We previously immunized cot-
ton rats with our wild type F containing VLPs and found 
that the resulting neutralizing antibody titers were unac-
ceptably low (unpublished observations). Here we report 
results of immunization of cotton rats with the VLPs 
containing the pre-fusion RSV F protein (Pre-F/F VLPs) 
comparing responses to RSV infection. We found that 
Pre-F/F VLPs, without the use of adjuvant, stimulated 
high titers of neutralizing antibodies and that Pre-F/F 
VLP immunization of these animals protected them from 
virus replication in the lungs and in nasal passages upon 
RSV challenge. Furthermore, we report that Pre-F/F VLP 
immunization of cotton rats is safe. There was no pathol-
ogy in these animals after immunization or after RSV 
challenge of immunized animals. Thus the pre-fusion F 
protein containing VLPs have characteristics required of 
a safe and effective RSV vaccine.
Methods
Cells, virus, plasmids
ELL-0 (avian fibroblasts), Vero cells, COS-7 cells, and 
HEp-2 cells were obtained from the American Type 
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Culture Collection. All cells were grown in DMEM sup-
plemented with penicillin, streptomycin, and containing 
5 % (Vero cells) or 10 % fetal calf serum. RSV, A2 strain, 
was obtained from Dr. Robert Finberg.
The cloning and expression of the NDV NP and M 
protein have been previously described [29]. The con-
struction, expression, and incorporation of the chimera 
protein NDV HN/RSV G (H/G) into VLPs have been pre-
viously described [23]. RSV G and RSV F sequences are 
from the A2 strain. Pre-fusion stabilized RSVF/NDV F 
(Pre-F/F) chimera protein was constructed as previously 
described [27]. Briefly, four point mutations, S155C, 
S190F, V207L, S290C, were introduced into the sequence 
encoding the ectodomain of the Gallus codon opti-
mized RSV F protein (amino acid 1-524). This mutated 
F protein ectodomain sequence was fused to sequences 
encoding the Gallus codon optimized T4 fibritin trimeri-
zation motif (foldon) [21, 30], the RSV F protein sequence 
encoding amino acids 521–524 (the membrane proximal 
serine-threonine rich region common to paramyxovirus 
F proteins), followed by the sequences encoding the NDV 
transmembrane and cytoplasmic domains.
Preparation of soluble forms of the pre‑fusion 
and post‑fusion F proteins and G protein
The soluble pre-F and post-F proteins were constructed 
as described by McLellan et al. [17, 21]. The soluble pre-F 
protein contained sequences encoding the RSV A2 F 
ectodomain (amino acids 1–513), containing the muta-
tions S155C, S190F, V207L, S290C, fused to sequences 
(synthesized by GenWiz) encoding the foldon, the 
thrombin cleavage site, strep Tag II, GSGSG linker, and 
6 ×  his tag [21]. The soluble post-fusion F protein was 
constructed using sequences encoding the RSV F protein 
ectodomain with the deletion of amino acids 137-146 
fused to sequences encoding the thrombin cleavage site, 
strep Tag II, GSGSG linker, and 6x his tag [21].
To prepare the soluble G protein, the G protein gene 
sequence encoding the first 47 amino acids was deleted 
by PCR mutagenesis forcing initiation of translation at 
the methionine at amino acid 48. The truncated G pro-
tein was robustly expressed and secreted by COS-7 cells.
Soluble F proteins and soluble G protein were prepared 
from COS-7 cells, transfected with pCAGGS vectors 
containing sequences encoding the soluble pre-F protein, 
the soluble post-F protein, or soluble G protein, as previ-
ously described [27]. Supernatants harvested from cells 
transfected with pCAGGS DNA without an inserted gene 
were obtained for negative controls (CAGGS target).
Antibodies
RSV F monoclonal antibody clone 131-2A (Chemicon) 
was used in RSV plaque assays. Monoclonal antibodies 
(mAb) 1112, 1200, and 1243, generous gifts of Dr. J. 
Beeler [31], and mAb 5C4, a generous gift of Dr. B. Gra-
ham [18], were used for ELISA analysis of VLPs and 
soluble F proteins [27]. Anti-RSV F HR2 peptide anti-
body [22] was used for quantification of soluble and VLP 
associated F proteins. Secondary antibodies specific 
for mouse and rabbit IgG were purchased from Sigma. 
Chicken anti-cotton rat IgG was purchased from Immu-
nology Consultant Laboratories.
Polyacrylamide gel electrophoresis, silver staining, 
and western analysis
For quantification of amounts of F and G proteins, VLPs 
or soluble F proteins were resolved on 8 % Bis–Tris gels 
(NuPage, Invitrogen). Silver staining of proteins in the 
polyacrylamide gels was accomplished as recommended 
by the manufacturer (Pierce). For Western blot analysis, 
proteins in the polyacrylamide gels were transferred to 
PVDF membranes using dry transfer (iblot, Invitrogen). 
Proteins were detected in the blots using anti-RSV HR2 
peptide antibodies.
VLP preparation, purification, and characterization
For preparations of VLPs to be used as immunogens, 
ELL-0 cells growing in T-150 flasks were transfected with 
cDNAs encoding the NDV M protein, NP, the chimeric 
protein H/G, and Pre-F/F as previously described [22, 
23]. At 24 h post-transfection, heparin was added to the 
cells at a final concentration of 10  μg/ml [23] to inhibit 
rebinding of released VLPs to cells. At 48, 72, and 96  h 
post-transfection, cell supernatants were collected and 
VLPs were purified by sequential pelleting and sucrose 
gradient fractionation as previously described [22, 23, 
32]. Concentrations of M, NP, and H/G proteins in the 
purified VLPs were determined by silver-stained poly-
acrylamide gels using marker proteins for standard 
curves [22, 32]. Determinations of amounts of F protein 
in VLPs or in soluble F protein preparations were accom-
plished by Western blots using anti-RSV F HR2 antibody 
for detection and comparing the signals obtained with 
a standard curve of purified F proteins as previously 
described [32].
ELISA protocols
For determination of titers of IgG in sera of immunized 
animals by ELISA, wells of microtiter plates (Costar) 
were coated with cell supernatants containing soluble 
pre-fusion F protein (13  ng/well), soluble post-fusion F 
protein (13 ng/well), or soluble G protein (approximately 
20  ng/well). Negative controls were equivalent volumes 
of supernatants from cells transfected with empty vec-
tor. Wells were then incubated in PBS-1 % BSA for 16 h. 
After washing wells three times with PBS, different 
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concentrations of cotton rat sera were added to each 
well and incubated for 2  h at room temperature. After 
six washes in PBS, chicken anti-cotton rat antibody cou-
pled to HRP was added in 50 μl PBS-1 % BSA and incu-
bated for 1.5  h at room temperature. Bound HRP was 
detected by addition of 50  μl TMB (3,3′5,5′-tetrameth-
ylbenzidin, Sigma) and incubation for 5-20 min at room 
temperature until blue color developed. The reaction was 
stopped with 50 μl 1 N sulfuric acid. Color was read in 
SpectraMax Plus Plate Reader (Molecular Devices) using 
SoftMax Pro software. Antibody titers were defined as 
the log10 of the dilution that yielded an optical density of 
twice background. Reagents required to measure precise 
ng amounts of protein specific IgG in the cotton rat sera 
are not available.
Preparation of RSV, RSV plaque assays, and antibody 
neutralization
RSV, strain A2, was propagated in HEp-2 cells after serial 
plaque-purification. The stock of virus utilized for the 
in vivo experiment, had a titer of 3.0 ×  108 pfu/ml. For 
virus titration, dilutions of virus or tissue samples were 
added to Hep-2 cells and incubated in 24-well plates at 
37  °C after overlaying the wells with 0.75  % methylcel-
lulose medium. After 4  days of incubation, the overlay 
was removed and the cells were fixed in 2.5  % glutaral-
dehyde solution containing 0.1  % crystal violet for 1  h, 
rinsed, and air-dried. Serum neutralization titers using 
RSV, strain A2, were determined as previously described 
[22, 23] and defined as the dilution of serum that reduced 
virus titer by 60 %.
Animals, animal immunization, and RSV challenge
Cotton rats (Sigmodon hispidus) 4–6  weeks of age were 
immunized by intramuscular (IM) inoculation of 50  μg 
(low dose) or 150 μg (high dose) total VLP protein/animal 
(7.7 and 23.4 μg F protein, respectively) in 0.1 ml of TNE 
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA). 
Boost immunizations of VLPs were 17 μg or 50 μg total 
VLP protein/animal (3.5 and 10.6  μg F protein, respec-
tively). A group of control animals were immunized by 
intranasal inoculation with RSV, strain A2, (1 × 105 pfu/
animal). For initial infections, boosts, or challenges of 
animals with RSV, the animals were lightly anesthetized 
with isoflurane. All animal procedures and infections 
were performed in accordance with the Sigmovir IACUC 
and IBC approved protocols.
Lung and nose viral titration
At 4 days after RSV challenge, five animals in each group 
were sacrificed and nasal tissue was harvested for virus 
titration. The lungs were excised en bloc and bisected for 
viral titration (left lobes) and histopathology (right lobes). 
Nasal tissue was obtained by dissection of the upper max-
illa after skin removal. Viral titers in the lungs and in the 
nose of RSV-infected cotton rats were determined as pre-
viously described [33] and adjusted by the weight of the 
tissue portion. Briefly, lung and nose homogenates were 
clarified by centrifugation and diluted in EMEM. Conflu-
ent HEp-2 monolayers were infected in duplicate with 
diluted homogenates in 24 well plates. After 1 h incuba-
tion at 37 °C in a 5 % CO2 incubator, the wells were over-
layed with 0.75 % methylcellulose medium. After 4 days 
of incubation, the overlay was removed and the cells 
were fixed with 0.1 % crystal violet stain for 1 h and then 
rinsed and air dried. Plaques were counted and virus titer 
was expressed as plaque forming units per gram of tissue. 
Viral titers were calculated as geometric mean ±  stand-
ard error for all animals in a group at a given time.
Pulmonary histopathology
The right lobes of lungs were dissected and inflated with 
10  % neutral buffered formalin to their normal volume, 
and then immersed in the same fixative solution. Follow-
ing fixation, the lungs were embedded in paraffin, sec-
tioned and stained with hematoxylin and eosin (H&E). 
Four parameters of pulmonary inflammation were eval-
uated: peribronchiolitis (inflammatory cell infiltration 
around the bronchioles), perivasculitis (inflammatory cell 
infiltration around the small blood vessels), interstitial 
pneumonia (inflammatory cell infiltration and thickening 
of alveolar walls), and alveolitis (cells within the alveolar 
spaces). Slides were scored blind on a 0–4 severity scale 
[34].
Statistical analysis
Statistical analyses (student T test) of data were per-
formed using Graph Pad Prism 7 software.
Results
Properties of VLPs containing a pre‑fusion RSV F protein
As previously described [27], the stabilized pre-fusion 
form of the RSV F protein (Pre-F/F) was incorporated into 
NDV VLPs by introducing into the previously character-
ized wild type F/F chimera protein [22] four point muta-
tions in the RSV F protein ectodomain and adding to the 
carboxyl terminus of the RSV F protein ectodomain a tri-
merization domain, the “foldon” sequence, as these were 
changes identified by McLellan et al. [21] to be necessary 
for the stabilization of the secreted form of the pre-fusion 
F protein trimer. In addition to the Pre-F/F protein, these 
VLPs contained the H/G chimera protein and the NDV 
NP and M proteins. Verification of the conformation of 
the Pre-F/F protein in VLPs [27] was accomplished using 
monoclonal antibody 5C4, which binds site ф specific to 
the pre-fusion form of the RSV F protein [18]. In addition, 
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the Pre-F/F VLPs bound monoclonal antibodies [27] spe-
cific to each of the previously defined F protein antigenic 
sites I, II, and IV [31] indicating that the Pre-F/F contain-
ing VLP also contains those sites as previously reported 
for soluble forms of the pre-fusion F protein [17, 18].
Anti‑F and anti‑G protein IgG immune responses to the 
VLPs
To assess the immunogenicity of the Pre-F/F VLPs (VLP-
H/G + Pre-F/F) in cotton rats, groups of ten cotton rats 
were immunized, by intramuscular injection (IM) with a 
low dose or a high dose of VLP-H/G + Pre-F/F or sham 
immunized with buffer. Other groups of 10 cotton rats 
were infected, intranasally (IN), with infectious RSV 
or not immunized. For assessment of the safety of VLP 
immunization, discussed below, a group of ten cotton 
rats was immunized IM with formaldehyde inactivated 
RSV (FI-RSV). At day 21 post prime immunization, all 
groups of cotton rats were boosted with buffer, VLPs, or 
FI-RSV by IM inoculation or with RSV by IN inocula-
tion. Sera were harvested by periorbital bleeding at 14, 
21, 35, and 49 days. Aliquots of sera obtained from the 
ten animals at each time point were pooled for deter-
mination of anti-F protein and anti-G protein IgG 
responses with time after immunization. Anti-F protein 
IgG responses of individual animals at day 49 were also 
determined.
To characterize the binding of anti-F protein antibod-
ies induced by the Pre-F/F VLPs to the pre-fusion and 
post-fusion forms of the F protein, we prepared soluble 
versions of both pre-F and post-F proteins to use as tar-
gets in ELISA as previously described [21, 35]. We have 
previously reported verification of the conformation of 
these soluble forms of F protein by the binding of repre-
sentative anti-F monoclonal antibodies to these secreted 
proteins in ELISA assays [27]. The binding of antibodies 
in cotton rat sera after VLP immunization or RSV infec-
tion to the soluble pre-fusion and post-fusion F proteins 
by ELISA is shown in Fig. 1.
Using soluble pre-fusion F protein as target, the day 
14 sera from VLP-H/G  +  Pre-F/F immunized animals 
contained slightly higher titers of F protein specific IgG 
than sera from RSV infected cotton rats. However, after 
boosting, binding to pre-fusion F protein increased sig-
nificantly in VLP-H/G  +  Pre-F/F immunized animals 
relative to those in sera obtained from RSV immunized 
animals (Fig. 1a, b). The dose of VLPs did not have a sig-
nificant effect on titers of pre-fusion F protein specific 
IgG antibodies. The variability between VLP immunized 
animals at day 49 was minimal (panel b). Thus the Pre-F 
containing VLPs were better at stimulating antibodies 
that would bind to the soluble pre-F protein than RSV 
infection.
Using the soluble post-fusion F protein as target, the 
titers of IgG in sera from VLP-H/G + Pre-F/F immunized 
animals were similar to those stimulated by RSV infec-
tion (Fig.  1c, d). The variability between animals at day 
49 was minimal (panel d). Boosting with VLPs or RSV 
had little effect on titers of post-F specific IgG. Different 
amounts of VLP immunogen had no effect on titers.
The levels of anti-G antibody responses after immu-
nization in the VLP immunized animals and in RSV 
infected animals were compared in an ELISA using 
soluble RSV G protein as target antigen. Figure 2 shows 
the titers of anti-G protein antibodies in pooled sera 
with time after immunization. Clearly VLP immuniza-
tion stimulated significantly higher levels of anti-G pro-
tein IgG responses than RSV infection. The differences 
between levels of anti-G protein antibodies in sera from 
high dose and low dose VLPs were not statistically 
significant.
Neutralizing antibody responses stimulated by the VLPs
Methods to determine neutralization titers vary from 
report to report. We chose to determine the neutral-
izing antibody titer of sera in a classical in  vitro plaque 
reduction assay. For these assays, pooled sera were used 
as were sera from individual cotton rats. For kinetics of 
induction of neutralizing antibodies, equal aliquots of 
sera from animals in each group obtained at four times 
after immunization were pooled and used to determine 
titers. Figure 3, panel a, shows an example of data used 
to determine these neutralization titers. Values obtained 
using buffer immunized animals (TNE) were taken as 
100  % to account for any nonspecific neutralization by 
pre-immune sera. Curves show plaques obtained after 
incubation of virus with increasing amounts of sera from 
buffer, RSV or VLP immunized animals. The dilution of 
sera resulting in reduction in titer by 60 % of the control 
was used to determine neutralization titers (indicated by 
the arrow for VLP low dose sera). Panel B shows neutrali-
zation titers with time after immunization determined in 
this way in pooled sera. Similarly, the titers of sera from 
each cotton rat were determined in sera harvested at day 
35 and day 49 (panels c and d). Figure 3 shows that after 
the prime immunization at day 14, RSV infection stimu-
lated slightly higher titers of neutralizing antibodies than 
VLP-H/G +  Pre-F/F immunization. However, the VLPs 
stimulated significantly higher titers of neutralizing anti-
bodies than RSV infection after the boost immuniza-
tion, a result obtained with pooled sera (panel b) as well 
as sera from individual animals (panels c and d). While 
titers were higher on average at day 35 than day 49, the 
difference was not statistically significant. The variabil-
ity in neutralizing titers between individual animals is 
shown in panels C and D.
Page 6 of 13Cullen et al. J Transl Med  (2015) 13:350 
The titers obtained after immunization of cotton rats 
with the wild type F containing VLPs (F/F) were 4–5 
log2, at day 43 (unpublished observations), which is 
approximately 22 times lower than those obtained after 
immunization with the pre-F containing VLPs. Thus 
the Pre-F containing VLPs are a much more effective 
immunogen than the wild type F containing VLPs and 
approximately three times more effective than RSV 
infection.
Protection of immunized animals from RSV challenge
To determine the protection from RSV replication 
afforded by VLP-H/G + Pre-F/F immunization, the virus 
titers in lungs and in nasal passages of immunized rats 
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Fig. 1 Anti-RSV F protein IgG immune responses to soluble Pre-F and Post-F target antigens. Figure shows titers with time after immunization of 
anti-F protein IgG in pooled sera that bind to the soluble pre-fusion F protein (a) and that bind to the soluble post-fusion F protein (c). Data shown 
are the averages of four separate determinations. b and d show titers in sera from individual cotton rats obtained at 49 days post immunization 
that bind to soluble pre-fusion F protein (b) or that bind to soluble post-fusion F protein (d). b Differences between the RSV group and the VLP 
groups are significant (p ≤ 0.0001) while the differences between VLPs low and VLPs high are not significant. d Differences between groups are not 
significant. Titers are defined in “Methods”. Pre-F/F VLPs low and Pre-F/F VLPs high indicate a dose (IM) of 50 and 150 µg total VLP protein/animal, 
respectively in the prime immunization. Boost immunizations, at day 21, were 17 and 50 μg/animal, respectively. RSV prime and RSV boosts were 
1 × 105 pfu/animal (IN)
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after RSV challenge were determined by plaque assay 
(Fig. 4). Clearly VLP-H/G + Pre-F/F immunization pro-
tected mice from RSV replication upon challenge as did 
previous RSV infection. VLP immunization completely 
protected the animals from replication in the lungs. VLP 
immunization reduced the titer of RSV in the nasal tissue 
by two logs.
Lung pathology in immunized animals after RSV challenge
We have previously reported that RSV challenge of 
VLP-H/G + F/F immunized mice did not result in lung 
pathology typical of that seen after RSV challenge of 
mice immunized with formalin inactivated RSV (FI-RSV) 
[22]. The cotton rat, which is more permissive for RSV 
than BALB/c mice, is a better animal model than mice 
for assessment of enhanced respiratory disease follow-
ing RSV challenge of an RSV vaccine candidate recipient. 
Thus the safety of immunization with Pre-F/F contain-
ing VLPs was assessed in this animal model. Five groups 
of cotton rats were immunized with two concentrations 
of VLP-H/G  +  Pre-F/F, sham immunized with buffer, 
infected with RSV, or not immunized. A sixth group 
was immunized with FI-RSV and served as the positive 
control for enhanced respiratory disease. All groups of 
animals were challenged, IN, with infectious RSV. At 
4–5  days following the challenge, lungs were harvested 
for histological analysis of inflammation and lung sec-
tions were scored blindly for peribronchiolitis, perivas-
culitis, interstitial pneumonia, and alveolitis. The scores 
are shown in Fig.  5, panels a–d, respectively. Immuni-
zation with FI-RSV recapitulated previously reported 
abnormal histology of the lung sections. The lungs of 
VLP-H/G +  Pre-F/F immunized cotton rats had scores 
that were statistically significantly lower than scores 
for FI-RSV immunized cotton rats and comparable to 
those of sham vaccinated or previously RSV infected 
animals. Figure  6 shows representative pictures of the 
H&E stained lung sections. Arrows indicate of inflamma-
tory cell infiltration in these lungs, which is significantly 
increased in lungs of FI-RSV immunized animals (pan-
els k and l) compared to that in lungs of VLP immunized 
animals (panels g–j), RSV infected (panels c and d), or 
mock immunized animals (panels e and f ). Arrowheads 
indicate alveolitis. Thickening of airway walls was also 
particularly enhanced in lungs of FI-RSV immunized 
animals (panel l). These results indicate that VLP vac-
cination of cotton rats does not stimulate enhanced res-
piratory disease, results similar to our previous reports of 
VLP immunization of mice.
Discussion
Numerous RSV vaccine candidates have been tested in 
animals and in human trials but no vaccine candidate 
has been licensed because of failure of these vaccine 
candidates to provide significant protection from RSV 
infection in humans [9, 10]. It is quite likely that all non-
replicating vaccine candidates, such as soluble protein, 
have contained predominantly the post fusion form of 
the F protein, which could account for failure of these 
candidates. Furthermore, a recent report indicates that 
the RSV F protein in virus particles exists largely in the 
post-fusion form suggesting the hypothesis that attenu-
ated RSV vaccine candidates or even wild type RSV infec-
tions present predominately the post-fusion F protein to 
the immune system [36]. As shown by Magro et al., most 
neutralizing antibodies in human or rabbit sera do not 
bind to the post-fusion F protein [20] and, as shown by 
McLellan et al., monoclonal antibodies that will bind the 
post-fusion F require far higher concentrations to neu-
tralize RSV than antibodies specific to the pre-fusion F 
protein [18]. Indeed, we have previously reported that 
RSV infection of mice induces approximately a ten to 
50-fold higher concentrations of IgG that bind to soluble 
post-fusion F targets than IgG that binds to soluble pre-
fusion F targets [27]. Such a phenomenon could account, 
in part, for the failure of infectious vaccine candidates or 
Fig. 2 Anti-RSV G protein IgG immune responses to soluble RSV 
G protein. Figure shows titers with time, after immunization with 
VLP-H/G + Pre-F/F or RSV, of anti-G protein IgG in pooled sera that 
bind to the soluble G protein. Data are the average of three separate 
determinations. VLP and RSV immunizations were as in Legend to 
Fig. 1. Boost immunization was at day 21
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wild type RSV to provide protection from subsequent 
infections.
McLellan et  al. reported mutations in the RSV F pro-
tein that stabilize the pre-fusion F protein [21]. We have 
incorporated these changes into the RSV F/NDV F (F/F) 
chimera protein in our ND VLPs and demonstrated that 
the Pre-fusion F/F containing VLPs induced, in BALB/c 
mice, significantly higher neutralization titers than VLPs 
constructed to contain a stabilized post-fusion F protein 
(Post-F/F) and significantly higher neutralization titers 
Fig. 3 Virus neutralization titers in sera from immunized cotton rats. a Representative data from plaque reduction assays of pooled sera obtained 
at 49 days post immunization and used to determine neutralization titers. Arrow indicates titer for VLP-low dose. b RSV A2 neutralization titers with 
time in pooled sera. Data are the average of five separate determinations by the method shown in a. Arrow indicates time of the boost immu-
nization. RSV A2 neutralization titers in sera from individual cotton rats at day 35 (c) and day 49 (d) post immunization, determined as shown in 
a. Immunogens are shown at the bottom of the panels. Differences between the RSV group and the VLP groups are significant (p = 0.0012 and 
p = 0.019, respectively). Differences between the two VLP groups are not significant
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than RSV infection [27]. Because the Post-F/F containing 
VLPs resulted in lower neutralization titers than the Pre-
F/F containing VLPs in mice, we chose to extend these 
studies by characterizing immune responses only to the 
Pre-F/F containing VLPs in cotton rats, a preferred ani-
mal model for testing of RSV vaccine candidates [28]. We 
did compare responses to the Pre-F/F containing VLPs 
to RSV infection in these animals. Cotton rats are more 
permissive to RSV infection than BALB/c mice. Thus 
RSV infection should stimulate better immune responses 
in cotton rats than in mice and provide a more stringent 
test of the effectiveness of the VLP immunization and the 
safety of the vaccine candidate in immunized animals.
The most important results presented here are neu-
tralization titers in cotton rats after VLP immunization. 
There have been, over the years, various estimates of the 
minimum serum neutralization titer required for pro-
tection from RSV challenge. Based on serum protective 
levels of the antibody palivizumab in infants, a minimal 
titer was defined as greater than or equal to 100 (recipro-
cal of dilution of sera resulting in 50 % reduction in RSV/
A2 virus titer in a plaque reduction assay) [21]. Another 
estimate, based on cotton rat studies, suggested titers of 
greater than 6, log 2, (60  % reduction in RSV/A2 virus 
titer) [37]. Other investigators have specified titers of 
380 or 390 (reciprocal of serum dilutions) [38] or 8.5 log2 
(60  % reduction) [39]. Our results showed that Pre-F/F 
containing VLPs, even after a single or prime immuniza-
tion, stimulated serum titers of 7.5 log2 (60 % reduction 
in titer) and a boost immunization stimulated the titers, 
on average, of between 9 and 10 (60 % inhibition). Thus 
these titers are considerably above all the threshold levels 
deemed necessary for a successful vaccine candidate. Sig-
nificantly, the VLPs stimulated better neutralizing anti-
body titers than RSV infection after a boost. This result 
demonstrates the effectiveness of the VLP as an immuno-
gen in spite of the fact that this particle is a non-replicat-
ing antigen in contrast to the RSV infection.
VLPs used for these experiments contained not only 
the Pre-F/F but also the RSV G protein ectodomain since 
antibodies specific to the G protein have been shown 
to be protective in  vivo [40–42]. Serum neutralization 
titers measured here in an in  vitro plaque reduction 
assay could be due to antibodies to both the RSV F and 
G protein. However, we have constructed a VLP contain-
ing only the H/G chimera protein and reported that the 
neutralization titers induced by this VLP in mice were 
extremely low, titers of approximately 3 log2 [23]. It is 
unlikely that the combination of G and F in a VLP will 
increase neutralization titers attributable to the G pro-
tein in these in vitro assays. However, the presence of G 
protein sequences in these VLPs likely has an important 
role in stimulation of protection from RSV replication 
and absence of increased lung inflammation upon RSV 
challenge. G protein has been associated with suppres-
sion of anti-RSV immune responses [43] and stimulation 
of enhanced respiratory disease [44]. Antibodies to G 
protein are known to decrease virus replication in lungs 
upon infection [45] and can ameliorate lung pathology 
after RSV challenge of FI-RSV immunized animals [46].
Fig. 4 Protection of immunized cotton rats from RSV challenge. Panels show titers of virus/gm in lung (left) and nasal (right) tissue four days after 
RSV A2 challenge of five cotton rats at 49 days post immunization. Immunogens are shown at the bottom for each group of five animals. Statisti-
cally significant differences between groups are indicated by p values at the top of each panel
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Consistent with the stimulation of robust neutralizing 
antibody titers, the VLP immunization induced protec-
tive responses in cotton rats. An RSV challenge of VLP 
immunized animals completely protected them from 
replication in lungs. While some virus was detected in 
nasal passages upon RSV challenge of these animals, 
titers were reduced by 2–2.5 log10 over the unimmu-
nized animals. RSV challenge of RSV infected cotton rats 
reduced nasal titers to undetectable levels. Perhaps this 
better protection from nasal passage replication by pre-
vious RSV infection compared to VLP immunization is 
related to the differing routes of immunization, intranasal 
vs intramuscular. Accordingly, intranasal immunization 
with the VLPs may stimulate better mucosal immunity 
and induce upper respiratory tract protection at levels 
comparable to those induced by previous RSV infection, 
a possibility to be explored in future experiments.
We have previously reported that, in mice, VLP-
H/G + Pre-F/F immunization and RSV infection stimu-
lated equivalent titers of IgG that bound to a soluble 
form of the post-fusion F protein in an ELISA [27]. Here 
we report similar results in cotton rats. However, as we 
Fig. 5 Assessment of lung pathology after RSV challenge of immunized cotton rats. Panels show scores of lung inflammation in ten cotton rats/
group immunized with immunogens indicated at the bottom of each panel and then challenged with RSV at 49 days post immunization. At 4–5 
days post challenge, lungs were harvested and tissue sections stained and scored for inflammation as described in "Methods". Differences between 
FI-RSV immunized animals and all other groups are statistically significant except for scores of perivasculitis, which are not significant. Differences 
between mock vaccinated, RSV infected, and VLP vaccinated animals in all categories are not statistically significant.
Page 11 of 13Cullen et al. J Transl Med  (2015) 13:350 
found in mice [27], VLP immunization of cotton rats 
stimulated significantly higher titers of IgG that bound 
to pre-fusion F protein than RSV infection, a result sug-
gesting that the VLP is more effective at presenting 
pre-fusion F specific epitopes to the cotton rat immune 
system than RSV infection.
In contrast to results in the murine system [27], a boost 
immunization of VLPs or RSV did not increase titers to 
the post-fusion F protein while titers in mice significantly 
increased upon a boost. While a second RSV infection 
(boost) only slightly increased titers to the pre-fusion F 
protein, VLP immunization significantly increased titers 
to the pre-fusion F protein, similar to results in mice and 
mirroring increases in neutralization titers. These results 
may indicate that the nature or induction of immune 
responses specific to the post-F protein in cotton rats 
are different from mice and different for antibodies to 
pre- and post F targets in cotton rats. Alternatively, the 
time interval between the prime and boost immuniza-
tion in the cotton rats may have been too short to detect 
a boost of post-fusion F specific serum antibody titers. In 
contrast to pre-fusion F specific titers, the higher anti-
body concentrations to the post-F protein after the prime 
in cotton rats may well have interfered with further stim-
ulation of antibodies specific to the soluble post-fusion F 
protein.
A very important property of any RSV vaccine candidate 
that must be addressed is safety, particularly for non-rep-
licating vaccines. This issue has dominated RSV vaccine 
development for years because an early vaccine candidate, 
a formalin-inactivated preparation of purified virus (FI-
RSV), not only failed to protect infants from infection, but 
also unexpectedly resulted in enhanced, life-threatening 
respiratory disease (ERD) upon subsequent infection with 
RSV (reviewed in [47–50]). We have reported that immu-
nization of mice with three different versions of RSV F 
containing VLPs did not stimulate enhanced respiratory 
disease upon RSV challenge [22, 23, 51] even at late times 
after immunization, in contrast to some other non-repli-
cating RSV vaccine candidates [52, 53]. Here, we showed, 
in cotton rats, that RSV challenge after VLP-H/G + Pre-
F/F immunization did not result in lung pathology while 
the positive control for ERD, FI-RSV, recapitulated the 
lung pathology repeatedly observed with this immunogen. 
Thus our results support the conclusion that immuniza-
tions with VLPs do not result in enhanced respiratory dis-
ease upon subsequent RSV infection, in contrast to some 
other non-replicating immunogens [52, 53].
Conclusions
Our results show that VLPs based on the core proteins 
of Newcastle disease virus M and NP and expressing on 
VLP surfaces the stabilized pre-fusion form of the RSV 
F protein as well as the RSV G protein induced in cot-
ton rats robust neutralizing antibody responses and pro-
tective responses. Importantly, our results show that this 
vaccine candidate does not induce enhanced respiratory 
disease upon RSV challenge, in contrast to responses 
to some non-replicating vaccine candidates [53, 54]. In 
addition, these VLPs should be particularly safe since 
they are non-replicating and incapable of a spreading 
infection characteristic of infectious virus vectored RSV 
vaccine candidates.
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